Within this precision-oncology framework, the clinical algorithm in Figure 2 synthesizes how to triage TP53-mutated CRC into rational treatment paths, emphasizing readiness for early-line deployment when host and tumor immunity are most malleable. The gene discussed is TP53; the disease is neoplasm.